Sapient provides discovery as a service to biopharma, non-profit, and academic organizations. Sapient’s biomarker discovery platform enables nontargeted, large-scale small molecule biomarker profiling (“metabolomics”) to rapidly probe the biomarker landscape of health and disease. The platform combines next-generation mass spectrometry technologies – that assay 11,000+ metabolites per biosample (cellular, preclinical, or human) – as well as advanced biocomputational / statistical approaches and a reference Human Biology Database of 100,000+ biosamples already analyzed on our mass spectrometry systems.

Together these approaches enable rapid identification, validation, and translation of circulating biomarkers of biological processes, disease mechanisms, and drug responsiveness which can be utilized across all phases of the drug discovery and development. For more information, visit sapient.bio.